MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells

被引:133
作者
Lee, J-J [1 ]
Drakaki, A. [2 ]
Iliopoulos, D. [1 ,3 ]
Struhl, K. [1 ]
机构
[1] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA
[3] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
miR-27b; PPAR gamma; NHE1; NF-kappa beta; inflammation; neuroblastomas; ACTIVATED-RECEPTOR-GAMMA; BREAST-CANCER; TERMINAL DIFFERENTIATION; KAPPA-B; EXPRESSION; ROSIGLITAZONE; MICRORNAS; AGONISTS; TRANSFORMATION; PROLIFERATION;
D O I
10.1038/onc.2011.543
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The peroxisome proliferators-activated receptor (PPAR)gamma pathway is involved in cancer, but it appears to have both tumor suppressor and oncogenic functions. In neuroblastoma cells, miR-27b targets the 30 untranslated region of PPAR gamma and inhibits its mRNA and protein expression. miR-27b overexpression or PPAR gamma inhibition blocks cell growth in vitro and tumor growth in mouse xenografts. PPAR gamma activates expression of the pH regulator NHE1, which is associated with tumor progression. Lastly, miR-27b through PPAR gamma regulates nuclear factor-kappa B activity and transcription of inflammatory target genes. Thus, in neuroblastoma, miR-27b functions as a tumor suppressor by inhibiting the tumor-promoting function of PPAR gamma, which triggers an increased inflammatory response. In contrast, in breast cancer cells, PPAR gamma inhibits NHE1 expression and the inflammatory response, and it functions as a tumor suppressor. We suggest that the ability of PPAR gamma to promote or suppress tumor formation is linked to cell type-specific differences in regulation of NHE1 and other target genes. Oncogene (2012) 31, 3818-3825; doi: 10.1038/onc.2011.543; published online 28 November 2011
引用
收藏
页码:3818 / 3825
页数:8
相关论文
共 45 条
  • [1] Troglitazone suppresses cell growth of KU812 cells independently of PPAR-γ
    Abe, A
    Kiriyama, Y
    Hirano, M
    Miura, T
    Kamiya, H
    Harashima, H
    Tokumitsu, Y
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 436 (1-2) : 7 - 13
  • [2] Aziz N, 1999, MOL CELL BIOL, V19, P1101
  • [3] Inflammation and cancer: back to Virchow?
    Balkwill, F
    Mantovani, A
    [J]. LANCET, 2001, 357 (9255) : 539 - 545
  • [4] MicroRNAs: Target Recognition and Regulatory Functions
    Bartel, David P.
    [J]. CELL, 2009, 136 (02) : 215 - 233
  • [5] Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas
    Braun, J.
    Hoang-Vu, C.
    Dralle, H.
    Huettelmaier, S.
    [J]. ONCOGENE, 2010, 29 (29) : 4237 - 4244
  • [6] Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types
    Burton, Jack D.
    Goldenberg, David M.
    Blumenthal, Rosalyn D.
    [J]. PPAR RESEARCH, 2008, 2008
  • [7] Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells
    Cellai, I.
    Benvenuti, S.
    Luciani, P.
    Galli, A.
    Ceni, E.
    Simi, L.
    Baglioni, S.
    Muratori, M.
    Ottanelli, B.
    Serio, M.
    Thiele, C. J.
    Peri, A.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 879 - 888
  • [8] In vivo effects of rosiglitazone in a human neuroblastoma xenograft
    Cellai, I.
    Petrangolini, G.
    Tortoreto, M.
    Pratesi, G.
    Luciani, P.
    Deledda, C.
    Benvenuti, S.
    Ricordati, C.
    Gelmini, S.
    Ceni, E.
    Galli, A.
    Balzi, M.
    Faraoni, P.
    Serio, M.
    Peri, A.
    [J]. BRITISH JOURNAL OF CANCER, 2010, 102 (04) : 685 - 692
  • [9] Chattopadhyay N, 2000, J NEUROSCI RES, V61, P67, DOI 10.1002/1097-4547(20000701)61:1<67::AID-JNR8>3.0.CO
  • [10] 2-7